Tirzepatide
CAS: 2023788-19-2
AA-Sequence:
Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSSGAPPPS-NH2
![](https://spacepeptides.com/wp-content/uploads/2022/09/tirzepatide-300x168.png)
Originator: Eli Lilly and Company
First marketed by: Eli Lilly and Company
Name of FDF: Mounjaro®
Original FDF: RTU solution for subcutaneous injection
Mode of Action
dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
Indications
Type 2 diabetes mellitus
Patent status
Subcutaneous formulation is still patented until 2032-05-13